- 1. US Food and Drug Administration. Medwatch 2004 safety alert. Zometa (zoledronic acid) injection. Available at: http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#zometa (accessed Mar 2005).
- 2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.
- 3. Ruggiero SJ, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534.
- 4. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253-4254.
- 5. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. Aust Prescriber 2004; 27: 32-33.
- 6. Pogrel MA. Bisphosphonates and bone necrosis. J Oral Maxillofac Surg 2004; 62: 391-392.
- 7. Schwartz HC. Osteonecrosis and bisphosphonates: correlation versus caution. J Oral Maxillofac Surg 2004; 62: 763-764.
- 8. Lugassy G, Shaham R, Nemets A, et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 2004; 117: 440-441.
- 9. The Maxillofacial Center for Diagnostics and Research. The history of maxillofacial osteonecrosis. Available at: http://maxillofacialcenter.com/NICOhistory.html (accessed Feb 2005).
- 10. Novartis Pharmaceuticals Australia. Aredia product information. Sydney: Novartis, May 2004.
- 11. Greenberg MS. Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 259-260.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.